Recent Updates
Recently added Catalysts
XCUR Negative Sentiment Score: 35/100

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q CHICAGO, IL.

Key Takeaway: Exicure, Inc. received a delinquency notice from Nasdaq due to its late filing of Form 10-Q for the quarterly period ending September 30, 2023. The company has been given 60 days to submit a compliance plan and may have up to 180 days to rectify the situation if the plan is approved. Despite the challenges of non-compliance and recent restructuring, Exicure is actively seeking strategic alternatives to enhance stockholder value.

Market Sentiment Analysis

POSITIVE FACTORS

  • Exicure is working diligently to complete the Form 10-Q.
  • The company has an opportunity to regain compliance within 180 days.
  • Exicure is exploring strategic alternatives to maximize stockholder value.

CONCERNS & RISKS

  • The receipt of a delinquency notice suggests serious financial compliance issues.
  • Failure to file the Form 10-Q could lead to further regulatory consequences.
  • Exicure's restructuring and suspension of clinical activities indicate instability.

Full Press Release Details

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
CHICAGO, IL. - November 28, 2023 - Exicure, Inc. ("Exicure" or the "Company") (Nasdaq XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on November 22, 2023 notifying the Company that, as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission (the "SEC").
Under Nasdaq's listing rules, Exicure has 60 calendar days to submit a plan to regain compliance. If the plan is accepted by Nasdaq, the Company can be granted up to 180 calendar days from the Form 10-Q due date, or until May 20, 2024, to regain compliance.
The Company is working diligently to complete its Form 10-Q and intends to file the Form 10-Q as soon as practicable to regain compliance with the Rule.
Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact may be deemed forward looking including, but not limited to, statements regarding the Company's current business plans and objectives, including the pursuit of strategic alternatives to maximize stockholder value. Words such as "plans," "expects," "will," "anticipates," "continue," "advance," "believes," "target," "may," "intend," "could," and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain such terms. Forward-looking statements are based on management's current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 27, 2023, as updated by the Company's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any of such statements to reflect future events or developments, except as required by law.
Lavinia exicuretx.com

Frequently Asked Questions

Why did Exicure receive a Nasdaq delinquency notice?

Exicure received the notice due to its late filing of the Form 10-Q.

What is the compliance deadline for Exicure?

Exicure has 60 days to submit a compliance plan; potentially up to 180 days.

What is Exicure's main focus as a biotechnology company?

Exicure develops nucleic acid therapies targeting RNA against validated targets.

What has Exicure recently suspended?

Exicure has suspended its clinical and development activities after restructuring.

Where can more information about Exicure be found?

More information is available on Exicure's official website, exicuretx.com.

Last updated: Nov 28, 2023